BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rezdiffra (Resmetirom) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rezdiffra (Resmetirom)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05500222-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT05500222)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pati
 ents With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/resmetirom#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05500222
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04951219-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT04951219)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Pat
 ients With Non-alcoholic Fatty Liver Disease (NAFLD)\, MAESTRO-NAFLD-Open-
 Label-Extension (MAESTRO-NAFLD-OLE)\nEstimated primary completion: March 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04951219
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143968-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rezdiffra (Resmetirom): Phase 2 readout est. (NCT07143968)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 2\, MASH / NASH.\nStudy: A Study
  to Evaluate the Use of Resmetirom in Participants With MASLD and HIV\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/resmetirom#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07143968
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830758-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rezdiffra (Resmetirom): Phase 1 readout est. (NCT07830758)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 1\, MASH / NASH.\nStudy: Resmeti
 rom in Patients With MASH and HFpEF\nEstimated primary completion: Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078307
 58
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07848191-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rezdiffra (Resmetirom): Phase 4 readout est. (NCT07848191)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 4\, MASH / NASH.\nStudy: Rezdiff
 ra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Ad
 ults With MASH and F2-F3 Fibrosis\nEstimated primary completion: November 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07848191
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03900429-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT03900429)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in P
 atients With NASH and Fibrosis\nEstimated primary completion: January 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03900429
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335601-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rezdiffra (Resmetirom): Phase 2 readout est. (NCT07335601)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 2\, MASH / NASH.\nStudy: Study t
 o Evaluate Resmetirom in Post-Liver Transplant Patients With MASH\nEstimat
 ed primary completion: August 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/resmetirom#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07335601
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763015-1161@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Rezdiffra (Resmetirom): Phase 2 readout est. (NCT07763015)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 2\, MASH / NASH.\nStudy: Study o
 f Resmetirom in Children and Adolescents With MASH\nEstimated primary comp
 letion: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 smetirom#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07763015
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
